Onconetix Statistics
Total Valuation
Onconetix has a market cap or net worth of $8.96 million. The enterprise value is $30.39 million.
Important Dates
The next estimated earnings date is Tuesday, December 3, 2024, before market open.
| Earnings Date | Dec 3, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Onconetix has 8.29 million shares outstanding. The number of shares has increased by 29.66% in one year.
| Current Share Class | 8.29M |
| Shares Outstanding | 8.29M |
| Shares Change (YoY) | +29.66% |
| Shares Change (QoQ) | +0.22% |
| Owned by Insiders (%) | 11.45% |
| Owned by Institutions (%) | 7.73% |
| Float | 3.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.37 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 20.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.10
| Current Ratio | 0.10 |
| Quick Ratio | 0.06 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.66 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -21.85% |
| Return on Capital (ROIC) | -152.46% |
| Revenue Per Employee | $121,979 |
| Profits Per Employee | -$4.43M |
| Employee Count | 12 |
| Asset Turnover | 0.03 |
| Inventory Turnover | 3.45 |
Taxes
| Income Tax | -83,392 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.04% in the last 52 weeks. The beta is 3.73, so Onconetix's price volatility has been higher than the market average.
| Beta (5Y) | 3.73 |
| 52-Week Price Change | -92.04% |
| 50-Day Moving Average | 3.89 |
| 200-Day Moving Average | 5.61 |
| Relative Strength Index (RSI) | 19.42 |
| Average Volume (20 Days) | 74,826 |
Short Selling Information
The latest short interest is 21,697, so 0.26% of the outstanding shares have been sold short.
| Short Interest | 21,697 |
| Short Previous Month | 20,287 |
| Short % of Shares Out | 0.26% |
| Short % of Float | 0.62% |
| Short Ratio (days to cover) | 0.23 |
Income Statement
In the last 12 months, Onconetix had revenue of $1.46 million and -$53.12 million in losses. Loss per share was -$104.97.
| Revenue | 1.46M |
| Gross Profit | -837,449 |
| Operating Income | -15.60M |
| Pretax Income | -45.82M |
| Net Income | -53.12M |
| EBITDA | -15.15M |
| EBIT | -15.60M |
| Loss Per Share | -$104.97 |
Full Income StatementBalance Sheet
The company has $930,541 in cash and $15.28 million in debt, giving a net cash position of -$14.35 million or -$1.73 per share.
| Cash & Cash Equivalents | 930,541 |
| Total Debt | 15.28M |
| Net Cash | -14.35M |
| Net Cash Per Share | -$1.73 |
| Equity (Book Value) | -28.73M |
| Book Value Per Share | -64.14 |
| Working Capital | -18.57M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$15.78 million and capital expenditures -$22,284, giving a free cash flow of -$15.81 million.
| Operating Cash Flow | -15.78M |
| Capital Expenditures | -22,284 |
| Free Cash Flow | -15.81M |
| FCF Per Share | -$1.91 |
Full Cash Flow StatementMargins
| Gross Margin | -57.21% |
| Operating Margin | -1,065.46% |
| Pretax Margin | -3,634.95% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -1,900.76% |